skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents

Review

(2888) Views  (983) Full article downloads

Authors: Ara Metjian, Charles S Abrams

Published Date December 2009 Volume 2009:3 Pages 499 - 513
DOI: http://dx.doi.org/10.2147/BTT.S5578

Ara Metjian1, Charles S Abrams2

1Department of Medicine, Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Abstract: Decades of basic science and clinical research have led to an increased understanding of the pathophysiology of immune thrombocytopenic purpura (ITP), the processes underlying thrombopoiesis, and the treatment of chronic ITP. Now, new agents are available to treat ITP in a nonimmunosuppressive fashion. Lessons learned from the clinical trials of recombinant human thrombopoietin (TPO) have led to the development of a novel class of compounds: nonimmunogenic agonists of the thrombopoietin receptor. Representing the first nonimmunosuppressive agents to treat chronic refractory ITP in decades, medications such as romiplostim and eltrombopag were recently approved by the US Food and Drug Administration. These new agents offer physicians a new tool for treating difficult cases of ITP in their medical armamentarium. Additional TPO mimetics are also being developed that show promise in vitro, and await future development.

Keywords: thrombocytopenia, immune-mediated thrombocytopenia, eltrombopag, romiplostim, thrombopoietin, thrombopoietin receptor








Readers of this article also read:

Therapeutic vaccines for malignant brain tumors
Treatment of immune thrombocytopenic purpura: focus on eltrombopag
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID
Finding a new drug and vaccine for emerging swine flu: What is the concept?
Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
Safety and immunogenicity of Salmonella typhimurium expressing C-terminal truncated human IL-2 in a murine model
Hepatitis B virus and Homo sapiens proteomewide analysis: A profusion of viral peptide overlaps in neuron-specific human proteins
Palliative treatment of malignant ascites: profile of catumaxomab
Managing idiopathic short stature: role of somatropin (rDNA origin) for injection
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • Journal Indexing

    See where all the Dove Press journals are indexed